N/A N=15 DualSculpting the Abdomen Using CoolSculpting
Body Fat Disorder
Primary: Proportion of Correctly Identified Photos by Blinded Reviewers — 28 photos
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=54 Study in Subjects Undergoing Complete Abdominoplasty
Postsurgical Pain
Primary: Pain Intensity Scores at 96 Hours at Rest Using Numerical Rating Scale (NRS) — 2.8; 2.0; 3.0; 2.8 score on a scale — p=0.2912
Phase 4 N=88 Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Opioid Use Disorder
Primary: Area Under the Plasma Concentration-time Curve From Study Day 1 to Day 29 (AUC0-28days) of Buprenorphine — 1640; 1720; 1570; 1870 h*ng/mL
N/A N=20 CoolSculpting in the Abdomen Using Applicator With and Without CCI
Body Fat Disorder
Primary: Percentage of Accurately Identified Pre-treatment Photos — 33; 23; 50; 23 photos
N/A N=60 Non-Invasive Reduction of Abdominal Fat
Fat Reduction
Primary: Proportion of Pre-treatment Images Correctly Identified — 128 photos — p=<0.001
Phase 3 N=793 Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
Central Abdominal Bulging
Primary: Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response — 37; 48 Participants — p=0.397
Phase 4 N=14 ABRA Abdominal Closure System in Open Abdomen Management
Open Abdomen
Primary: Primary Closure Rate — 75; 67 % of participants
N/A N=278 Post-operative Patient Positioning Device for Improvement of Post-Operative Pain
Pain, Postoperative
Primary: Total Morphine Milliequivalent (MME) Use Postoperatively After Cesarean Delivery — 52; 68 Morphine milligram equivalents
N/A N=70 SlimShape Device for Abdominal Fat and Circumference Reduction
Fat Disorder
Primary: Change in Fat Thickness at Final Follow-up Compared to Baseline — -1.76 millimeters
Phase 2 N=276 In Vivo Preoperative Skin Preparation Persistence Evaluation
Bacterial Recovery of Skin Flora Post-product Application
Primary: Measurement of Skin Flora Recovery Post-prep Application — 1.39; 1.15; 1.97; 1.82 log10 CFU/cm^2 — p=0.13
N/A N=9 Toward an Automated Method of Abdominal Fat Segmentation of MR Images
Obesity
Primary: Visceral Fat Volume With Automated Analysis — 994 cubic centimeters
N/A N=20 Estimating Patient Size From a Single Radiograph
Testing a Computational Model to Estimate Patient Size
Primary: Accuracy of the Computational Model — 5.8 percentage agreement (est/measured)
N/A N=12 Performance Evaluation of the truSculpt Radiofrequency Device for Lipolysis of Abdominal Fat
Body Fat
Primary: Number of Participants Who's Abdominal Tissue Showed Necrosis or Inflammatory Immune Cell Response — 10; 0 Participants
Phase 2 N=202 D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection
Abdominal Surgery · Colon Surgery · Post-Op Infection
Primary: The Combined Infection and Mortality Rate Within 30 Days Post Index Surgery — 24; 10 Participants — p=0.0086
N/A N=46 Micropore Closure Kinetics at Various Body Sites
Healthy
Primary: Micropore Re-sealing Kinetics — 58.29; 60.34; 63.09 hours
Phase 3 N=640 Clinical Evaluation of Patient Preoperative Prep
Surgical Skin Preparation
Primary: Bacterial Reduction — 4.04; 4.01; 1.60 log10 cfu/cm^2
Phase 2 N=10 Histopathology Following CCH Injection
Characteristics of Subcutaneous Tissue
Primary: Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH — 2; 1; 1; 2 Participants
N/A N=40 Diagnostic Ultrasound for Measuring Fat of the Body
Subcutaneous Fat
Primary: Difference in Thickness of Subcutaneous Fat at Different Anatomic Sites on the Body — .56; .60; .83; 1.65 average fat measurement (cm)
N/A N=34 Single Breath Hold Abdominal MRI
Abdominal MRI
Primary: Motion Artifact Scores — 1.8; 2.4 scores on a scale — p=<0.001
N/A N=180 Study Evaluating Severe Surgical Site Infections (SSIs) Following Contaminated Or Dirty-infected Abdominal Surgery
Surgical Wound Infection · Postoperative Wound Infection
Primary: Percentage of Participants With Pre-surgical Morbidities — 47.8; 48.9; 26.7; 23.3 percentage of participants — p=0.881
N/A N=75 Trim II for Noninvasive Lipolysis and Circumference Reduction of Abdomen.
Circumference Reduction of Abdomen
Primary: Evaluation of Change in Abdomen Circumference Using Tape Measurements in cm at the 3 Months Follow-up Visit Comparing to Baseline. — 89.5 CM
Phase 3 N=219 Evaluation of N1539 Following Abdominoplasty Surgery
Pain, Post-operative
Primary: Summed Pain Intensity Difference Over the First 24 Hours (SPID24) — -4262.1; -3535.7 units on a scale — p=0.0145
N/A N=30 Clinical Evaluation of the Safety and Efficacy of a 1060nm Diode Laser (Abdomen)
Fat Atrophy
Primary: Number of Before and After Photograph Sets Correctly Identified by Independent, Blinded Evaluators — 54 Photo sets
N/A N=253 Laparoscopic Versus Transabdominal Ultrasound in Morbidly Obese Patients
Cholelithiasis · Ultrasonography · Laparoscopic Gastric Bypass
Primary: Cholelithiasis on Transabdominal Ultrasound Versus Laparoscopic Ultrasound. — 61; 60 participants — p=0.763
N/A N=62 UltraShape Power for Abdominal Fat and Circumference Reduction
Excess Abdominal Fat
Primary: Change in Abdominal Fat Thickness Compared to Baseline as Measured by Ultrasound — -10.5 percentage change
Phase 2 N=20 Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses
Abdominal Abscess · Pelvic Abscess
Primary: Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage — 3; 7 participants
N/A N=5 Proximal Humerus Site for Anesthesia
Intraosseous Vascular Access
Primary: Intraosseous Infusion Flow Rate — 2433.33 mL / hour
N/A N=634 Transabdominal and Transvaginal Sonography in Medical Abortion
Abortion Early
Primary: Percentage of Subjects in Each Ultrasound Group With Additional Testing — 63; 14 Participants
Phase 2 N=445 Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery
Surgical Site Infections
Primary: Number of Patients With Surgical Site Infections — 42; 14; 25 participants
N/A N=30 Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction
Metastatic Carcinoma
Primary: Number of Participants With SABR Successfully Delivered in One Fraction — 30 Participants